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Idelalisib sensitivity and mechanisms of disease progression in
relapsed TCF3-PBX1 acute lymphoblastic leukemia
S Eldfors1, H Kuusanmäki1,2, M Kontro2, MM Majumder1, A Parsons1, H Edgren3, T Pemovska1, O Kallioniemi1, K Wennerberg1,
N Gökbuget4, T Burmeister5, K Porkka2 and CA Heckman1
TCF3-PBX1 (E2A-PBX1) is a recurrent gene fusion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), which is caused by the
translocation t(1;19)(q23;p13). TCF3-PBX1 BCP-ALL patients typically beneﬁt from chemotherapy; however, many relapse and
subsequently develop resistant disease with few effective treatment options. Mechanisms driving disease progression and therapy
resistance have not been studied in TCF3-PBX1 BCP-ALL. Here, we aimed to identify novel treatment options for TCF3-PBX1 BCP-ALL
by proﬁling leukemia cells from a relapsed patient, and determine molecular mechanisms underlying disease pathogenesis and
progression. By drug-sensitivity testing of leukemic blasts from the index patient, control samples and TCF3-PBX1 positive and
negative BCP-ALL cell lines, we identiﬁed the phosphatidylinositide 3-kinase delta (p110δ) inhibitor idelalisib as an effective
treatment for TCF3-PBX1 BCP-ALL. This was further supported by evidence showing TCF3-PBX1 directly regulates expression of
PIK3CD, the gene encoding p110δ. Other somatic mutations to TP53 and MTOR, as well as aberrant expression of CXCR4, may
inﬂuence additional drug sensitivities speciﬁc to the index patient and accompanied progression of the disease. Our results suggest
that idelalisib is a promising treatment option for patients with TCF3-PBX1 BCP-ALL, whereas other drugs could be useful depending
on the genetic context of individual patients.
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INTRODUCTION
The t(1;19)(q23;p13) translocation is a recurrent aberration
occurring in 3–5% of acute lymphoblastic leukemias (ALLs) and
results in the fusion protein TCF3-PBX1, which is an oncogenic
transcription factor.1 The majority of human TCF3-PBX1 BCP-ALLs
are pre-B-cell receptor positive,2–4 and the expression of pre-B-cell
receptor genes has been shown to be directly upregulated by
TCF3-PBX1.4 The pre-B-cell receptor signaling pathway is activated
in TCF3-PBX1 BCP-ALLs, and its inhibition has been identiﬁed as a
promising approach for treating this disease.1,5
With current treatment regimens, the prognosis in adult
TCF3-PBX1 BCP-ALL patients is similar to that of other adult
ALLs.6 Most patients with TCF3-PBX1 BCP-ALL beneﬁt from
chemotherapy, however, the disease often recurs, at which point
there are few effective treatment options. Targeted drugs may
offer further opportunities for improving treatment outcome, and
may also be associated with lower toxicity. However, few studies
have sought to identify effective new drugs to treat TCF3-PBX1
BCP-ALL. Furthermore, mechanisms driving disease progression in
TCF3-PBX1 BCP-ALL are unknown.
In this study, we aimed to identify novel treatment options for
TCF3-PBX1 BCP-ALL by proﬁling samples from a 25-year-old
relapsed t(1;19)-positive ALL patient. Using a drug-sensitivity
assay testing 302 investigational and approved anti-neoplastic
drugs, we identiﬁed several targeted therapies showing efﬁcacy
towards TCF3-PBX1 BCP-ALL. Molecular proﬁling of the patient
cells by exome and RNA sequencing, plus phospho-proteome
analysis provided supporting evidence and rationale for the
efﬁcacy of speciﬁc inhibitors. Validation using cell lines and
control samples provided support for the use of idelalisib, an
inhibitor of phosphatidylinositide 3-kinase delta (p110δ), for
TCF3-PBX1 BCP-ALL.
MATERIALS AND METHODS
Patient samples
Bone marrow (BM) aspirates, peripheral blood and skin biopsy samples
were collected after written informed consent was obtained and according
to protocols approved by local Institutional Review Boards in accordance
with the Declaration of Helsinki. Blast counts for the index patient samples
were 76-90%. Cohort samples were taken from patients diagnosed with
Ph+ and Ph− ALL, B-cell ALL, T-cell ALL, chronic lymphocytic leukemia
(CLL), mantle cell lymphoma (MCL), chronic myeloid leukemia (CML),
chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia
(AML). In addition, BM aspirates were collected from healthy donors
(n=13). The mononuclear cell (MNC) fractions of the BM and blood
samples were isolated by gradient centrifugation (Ficoll-Paque PLUS,
GE Healthcare, Little Chalfont Bucks, UK). The BCP-ALL patient samples and
their characteristics are listed in Supplementary Tables S1 and S2.
Ex vivo drug-sensitivity testing
Ex vivo drug-sensitivity testing was performed as previously described.7
Freshly isolated, patient-derived leukemia cells were cultured in Mono-
nuclear Cell Medium (PromoCell, Heidelberg, Germany) and seeded in
pre-drugged 384-well plates that included 302 active agents. The
compound collection included the majority of FDA/EMA-approved anti-
cancer drugs and several investigational compounds. The drugs were
plated in ﬁve different concentrations in 10-fold dilutions using an acoustic
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liquid handling device (Echo 550; Labcyte Inc., Sunnyvale, CA, USA). After
72 h incubation, cell viability was measured using the CellTiter-Glo
luminescence assay (Promega, Madison, WI, USA) with the PHERAstar
(BMG LABTECH, Ortenberg, Germany) or SpectraMax Paradigm (Molecular
Devices, Sunnyvale, CA, USA) plate readers. Drug sensitivities were
quantiﬁed using a drug-sensitivity score, which is a modiﬁed area under
the curve-based metric that has been described previously.8
Drug testing of BCP-ALL cell lines
TCF3-PBX1 positive (697, KASUMI-2, RCH-ACV) and negative cell lines
(TOM-1, MHH-CALL-4, MUTZ-5) were purchased from DSMZ (Leibniz
Institute, Braunschweig, Germany) and cultured in Gibco RPMI medium
(Thermo Scientiﬁc, Carlsbad, CA, USA) supplemented with 15% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin.
The compounds were pre-plated in 384-well plates at seven different
concentrations using the Echo 550 acoustic dispenser. The cells were
seeded in 25 μl volume of medium at the following densities: 697 and
RCH-ACV, 2500 cells/well; TOM-1, KASUMI-2, 5000 cells/well; and MUTZ-5
and MHH-CALL-4, 7000 cells/well. After 72 h, cell viability was measured
using the CellTiter-Glo assay. The data were normalized to the negative
control (dimethyl sulfoxide vehicle only) and the positive control wells
(100 μmol/l benzethonium chloride).
Exome sequencing and mutation analysis
Diagnosis BM, two relapse BM and skin biopsy samples were exome
sequenced. DNA was isolated with the DNeasy Blood and Tissue kit
(Qiagen, Hilden, Germany). Exome capture was performed using 3 μg DNA
and the NimbleGen SeqCap EZ v2 capture kit (Roche NimbleGen, Madison,
WI, USA). Sequencing was performed on the HiSeq 2500 instrument
(Illumina, San Diego, CA, USA). For the skin biopsy and BM tumor samples,
4 × 107 and 1× 108 2 × 100-bp reads were sequenced per sample,
respectively.
Reads were processed and aligned to the GRCh37 reference-genome as
previously described.9 Somatic mutations were called from the exome-
capture target regions using the VarScan2 somatic algorithm10 with the
following parameters: strand-ﬁlter 1, min-coverage-normal 8, min-
coverage-tumor 6, somatic-P-value 0.01, min-var-freq 0.05. Mutations were
annotated using SnpEff 4.03(ref. 11) with Ensembl v68 database. Mutations
were visually validated using the Integrative Genomics Viewer (Broad
Institute, Cambridge, MA, USA). Copy number aberrations were identiﬁed
as described in the Supplementary Information.
RNA sequencing
RNA sequencing was performed on two relapsed BM samples from the
index patient and in a cohort of acute leukemias consisting of AMLs and
ALLs (N= 66). RNA was prepared with Qiagen AllPrep kit then ribosomal
RNA was depleted using a Ribo Zero rRNA Removal Kit (Epicenter, Madison,
WI, USA). Ribo-depleted RNA was reverse-transcribed to double-stranded
cDNA using a SuperScript Double-Stranded cDNA Synthesis Kit (Thermo
Scientiﬁc). Random hexamers (New England BioLabs, Ipswich, MA, USA)
were used to prime the ﬁrst-strand synthesis reaction. The Epicenter
NextEra kit was used to prepare the RNA sequencing libraries. High-
molecular-weight buffer and 50 ng of cDNA was used for tagmentation.
The fragmented cDNA was puriﬁed using Agencourt AMPure XP SPRI
beads (Beckman Coulter, Brea, CA, USA). Sequencing libraries were size-
selected to 350–700 bp fragments in 2% agarose gel and then puriﬁed
using the Qiagen QIAquick gel-extraction kit. The Illumina HiSeq2500
platform with the TruSeq SBS Kit v3-HS reagent kit was used to perform
paired-end sequencing to 100 bp read length. The NextEra Read Primers 1
and 2 as well as the NextEra Index Read Primer were used for paired-end
sequencing and index-read sequencing, respectively. RNA-sequence data
were analyzed as described previously.12 Exome and RNA sequence data
has been deposited at the European Genome-phenome Archive
(EGA, http://www.ebi.ac.uk/ega/), which is hosted by the EBI, under
accession number EGAS00001001876.
RESULTS
Case history of the index patient
The index patient (668) was a previously healthy 25-year-old male
when diagnosed with BCP-ALL. The patient presented with
lymphadenopathy and splenomegaly. Leukemic blasts were
CD20-positive. Conventional karyotyping and ﬂuorescence in situ
hybridization analyses of BM cells revealed the presence of an
unbalanced der(19)t(1;19)(q23;p13) translocation and isochromo-
some i(9q). The patient received rituximab, cyclophosphamide,
vincristine, doxorubicin and dexamethasone induction and
consolidation therapy, followed by an allogeneic hematopoietic
stem cell transplant from a matched unrelated donor while in the
ﬁrst complete remission (Figure 1). The ﬂuorescence in situ
hybridization analysis was negative for t(1;19) cells before
transplant. The ﬁrst relapse occurred at 2 years and 4 months
after the initial transplantation. Cytogenetic analysis showed a
t(1;19), i(9q) karyotype. The patient received rituximab, cyclophos-
phamide, vincristine, doxorubicin and dexamethasone induction
therapy that resulted in a complete morphological remission, but
with minimal residual disease detected by ﬂuorescence in situ
hybridization. The patient was consolidated with clofarabine,
cytarabine and etoposide before a second allogeneic hemato-
poietic stem cell transplant. After 18 months, the patient again
relapsed, with karyotype analyses indicating further clonal
evolution. The patient achieved a complete remission after
receiving a combination of ﬂudarabine, cytarabine and G-CSF
(FLAG) therapy, but minimal residual disease was detected by
immunophenotyping. He then received a 14-week course of
consolidation therapy with dasatinib (25–50 mg daily) and
pegylated interferon α (30 μg/week). Due to cytopenias, the
treatment was not administered continuously. The minimal
residual disease level remained stable during the treatment until
disease progression. FLAG therapy was restarted with no
response. The patient died at 5 years and 5 months after the
initial diagnosis.
Ex vivo drug-sensitivity testing reveals several active targeted
agents for relapsed TCF3-PBX1 BCP-ALL
To identify novel treatment options for relapsed TCF3-PBX1 BCP-
ALL, we assessed the ex vivo sensitivity of BM mononuclear cells
from the index patient against a panel of 302 small molecule
inhibitors. The cells were highly sensitive to many targeted agents
compared with other samples analyzed under similar conditions.
Identiﬁed sensitivities included PI3K inhibitors, PI3K/mTOR dual
kinase inhibitors, ATP-competitive mTOR kinase inhibitors, rapalogs,
bromodomain (BET) inhibitors, histone deacetylase inhibitors, BCL2
inhibitors and corticosteroids (Figure 2a and Supplementary Table
S4). Compared with the ﬁrst proﬁled relapse sample 668_1, the later
sample 668_4 was less sensitive to most drugs, indicating that
drug-resistant clones were selected as the disease progressed.
Interestingly, although sensitivity was reduced for most drugs, the
sensitivity to BET inhibitor I-BET151 or the histone deacetylase
inhibitors mocetinostat and entinostat did not change (Figure 2a).
Ibrutinib and dasatinib have previously been suggested to be
effective against TCF3-PBX1 BCP-ALLs.4,5 The cells from the ﬁrst
Figure 1. Clinical timeline of TCF3-PBX1 BCP-ALL index patient 668
with treatment, sampling and analysis history. Allo-HSCT, allogeneic
hematopoietic stem cell transplant.
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relapse sample (668_1) were sensitive to ibrutinib and had
sensitivity comparable to cells from a chronic lymphocytic
leukemia (CLL) patient (Figure 2b). However, the later relapse
sample (668_4) lost sensitivity to ibrutinib (Figure 2b). Compared
with other patient samples tested, the cells from both relapse
samples of the TCF3-PBX1 BCP-ALL patient exhibited average
sensitivity to dasatinib (Figure 2a). This was in contrast to cells
from a blast-crisis chronic myeloid leukemia (BC-CML) patient,
which were highly sensitive to dasatinib (Figure 2c).
TCF3-PBX1 ALLs are sensitive to the PI3K-delta inhibitor idelalisib
Both relapse samples of the TCF3-PBX1 BCP-ALL index patient
were highly sensitive to idelalisib (CAL-101, GS-1101). The samples
exhibited similar sensitivity as a CLL sample, which was used as
a positive control for idelalisib sensitivity (Figure 3a). Although
cells from the later relapse sample were slightly less sensitive to
idelalisib compared with the earlier sample, the cells remained
highly sensitive compared with other hematological tumors and
healthy controls. Notably, the index patient cells were among
the most sensitive to idelalisib compared with other hematolo-
gical tumors (n= 112) and healthy bone marrow controls
(n= 13; Figure 3b).
To determine whether idelalisib sensitivity is common to all
BCP-ALL or speciﬁc for TCF3-PBX1 positive BCP-ALL, we assessed
the sensitivity of both TCF3-PBX1 positive and negative BCP-ALL
cell lines. We found that two of three TCF3-PBX1 positive cell lines
tested, Kasumi-2 and RCH-ACV, were sensitive to idelalisib;
whereas the three TCF3-PBX1 negative cell lines tested were
insensitive. The TCF3-PBX1 positive line 697, which lacked
sensitivity to idelalisib, harbors an oncogenic NRAS p.G12D
mutation,13 potentially affecting idelalisib response.
We also tested sensitivity to BET, histone deacetylase and BCL2
inhibitors as well as to temsirolimus and ruxolitinib in the same
cell lines. However, we did not observe a consistent difference in
sensitivity to these compounds between the TCF3-PBX1 positive
and negative cell lines (Supplementary Figure S1).
Clonal evolution of TCF3-PBX1 BCP-ALL
To determine the mechanisms mediating drug sensitivity and
resistance as well as disease progression in TCF3-PBX1 BCP-ALL, we
performed exome sequencing on BM mononuclear cells collected
at diagnosis and two relapses from the index patient (Figure 1).
We identiﬁed an MTOR p.M1724_Q1725insV in-frame insertion
mutation, a PHF6 loss-of-function mutation, plus chromosomal
aberrations t(1;19) and i(9q) in all the samples (Table 1). The
formation of isochromosome i(9q) causes the heterozygous
deletion of 9p, which contains the tumor-suppressor gene
CDKN2A as well as B-cell transcription factor PAX5.
Relapse-speciﬁc mutations included TP53 loss-of-function
mutations (Table 1). Following the second allogeneic hemato-
poietic stem cell transplant, the leukemia cells had acquired TP53
p.R273_V274insAGP. In the subsequent relapse, the cells had
Figure 2. Drug-sensitivity results for the index patient cells compared with other tested patient samples. (a) Cells from TCF3-PBX1 BCP-ALL
patient 668 are compared with a cohort of hematological tumors tested under similar conditions, including ALL, AML and CLL. The values
establish the activity range for each compound in the ex vivo assay. Asterisks indicate drugs approved for clinical use. (b) Dose response
of cells from TCF3-PBX1 BCP-ALL patient 668 and a CLL patient to ibrutinib. Results are normalized to the viability of cells treated with the
vehicle (DMSO). (c) Dose response of cells from TCF3-PBX1 BCP-ALL patient 668, a CLL patient and a BC-CML patient to dasatinib.
DMSO, dimethyl sulfoxide.
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additionally acquired TP53 p.R283_T284insR and a subclonal del
(17p). To determine at which point during the disease evolution
the observed TP53 insertion mutations occurred, we validated the
mutations using high-sensitivity amplicon sequencing of the
diagnosis and relapse samples. The TP53 mutations were not
detected in the diagnosis sample, indicating that these mutations
were acquired during therapy. An additional focal deletion of
CDKN2A was present in the earlier 668_1 relapse sample but
was not detected in the later 668_4 sample, indicating that
the dominant clone changed between these time points.
Non-synonymous mutations and chromosomal aberrations iden-
tiﬁed in the index patient’s samples are listed in Supplementary
Table S5, and genes with aberrant somatic copy number are listed
in Supplementary Table S6.
TCF3-PBX1 regulates PIK3CD expression by binding to leukocyte-
speciﬁc promoters
To further deﬁne mechanisms mediating drug responses in
TCF3-PBX1 BCP-ALL, we proﬁled the patient cells by RNA
sequencing. The PIK3CD gene encodes the idelalisib target
protein p110δ. PIK3CD expression has been shown to be
upregulated in the majority of TCF3-PBX1 BCP-ALLs and to be a
regulatory target of TCF3-PBX1.4 We found that compared with
data from 66 leukemia samples with other aberrations, both
relapsed samples from the index patient had higher expression of
PIK3CD (Figure 4a).
To better understand the mechanism that underlies the
regulation of PIK3CD in TCF3-PBX1 BCP-ALL, we analyzed publicly
available chromatin immunoprecipitation sequence data of TCF3,
PBX1 and p300 from TCF3-PBX1 ALL ICN12.4 P300 is a transcrip-
tional co-activator that is known to bind to the TCF3-PBX1 protein.
Our analysis showed that the TCF3-PBX1 protein binds to
promoters 1 and 2 of PIK3CD (Figure 4b). These promoters have
been shown to be used by leukocytes to drive high level of
PIK3CD expression.14,15
High CXCR4 expression in relapse samples from the index
TCF3-PBX1 BCP-ALL patient
By RNA sequencing, we also observed that the chemokine
receptor gene CXCR4 was among the most highly expressed
protein-coding genes in both relapse samples of the index patient.
The patient cells had high CXCR4 expression compared with 66
acute leukemia samples with other aberrations (Figure 5a).
To determine whether CXCR4 expression is common in B-ALL or
a consequence of the t(1;19), we analyzed CXCR4 expression in
leukemia cells from other B-ALL patients. By qRT-PCR analysis,
CXCR4 expression was exceptionally high in a relapse sample from
the index patient (668_1), whereas diagnosis phase TCF3-PBX1
BCP-ALL samples (n= 14) showed lower CXCR4 expression levels.
The remaining B-ALL cases (n= 4) had other aberrations. The
results showed that the index patient sample obtained at relapse
was the only TCF3-PBX1 BCP-ALL sample with high CXCR4
expression (Figure 5b).
Analysis of chromatin immunoprecipitation sequence data
showed that TCF3-PBX1 binds to the CXCR4 promoter, intron
Figure 3. Idelalisib sensitivity of TCF3-PBX1 BCP-ALL patient cells and cell lines compared with cells lacking the fusion. (a) Ex vivo drug-
sensitivity testing results for leukemia cells obtained from a TCF3-PBX1 BCP-ALL index patient samples (668_1 and 668_4). The values for the
patient samples are shown compared with the average values for BM-MNCs obtained from 13 healthy control individuals and to a CLL sample.
The data are normalized to the viability of cells treated with the vehicle (DMSO). (b) The distribution of ex vivo drug sensitivities for a cohort of
hematological tumors and BM-MNCs obtained from healthy individuals. (c) Viability in TCF3-PBX1 positive and negative BCP-ALL-cell lines in
response to idelalisib after a 3-day incubation. The means of three replicate experiments are shown, and the error bars indicate± s.d. DMSO,
dimethyl sulfoxide; MNC, mononuclear cell.
Table 1. Somatic mutations and chromosomal aberrations in known
cancer genes in leukemia cells from the TCF3-PBX1 BCP-ALL index
patient
Gene Mutation type Mutant variant allele frequency
Diagnosis Relapse
(668_1)
Relapse
(668_4)
PHF6 p.Q121* 86% 92% 84%
MTOR p.M1724_Q1725insV 47% 46% 42%
TP53 p.R273_V274insAGP 0% 47% 60%
TP53 p.R283_T284insR 0% 0% 16%
Translocation and CNAs
TCF3-
PBX1
t(1;19)(q23;p13) x x x
CDKN2A i(9q) Heterozygous deletion x x x
CDKN2A Homozygous deletion x
PAX5 i(9q) Heterozygous deletion x x x
TBL1XR1 Heterozygous deletion x x
TP53 Subclonal deletion x
Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia;
CNA, copy number aberration.
Idelalisib for TCF3-PBX1 positive acute leukemia
S Eldfors et al
54
Leukemia (2017) 51 – 57
and upstream enhancer region indicating that TCF3-PBX1
participates in the regulation of CXCR4 gene expression in
TCF3-PBX1 positive cells. RNA-sequence data from the index
patient cells showed expression of non-coding enhancer RNA
(eRNA) from the CXCR4 enhancer region (Figure 5c), indicating the
presence of open chromatin that enables binding of transcription
factors.
Novel MTOR p.M1724_Q1725insV somatic mutation associated
with sensitivity to mTOR inhibitors
The drug proﬁling results showed that the index patient cells
were highly sensitive to mTOR inhibitors including rapalogs and
mTOR kinase inhibitors (Figure 2a). Exome sequence showed the
cells harbored a heterozygous MTOR somatic mutation p.
M1724_Q1725insV, which was present in all samples from
diagnosis to relapse (Table 1). To assess mTOR activity in the
patient cells, we analyzed the phosphorylation of downstream
targets of mTOR kinase: S6K1 and Akt by phospho-proteome array
(Supplementary Table S7) and immunoblotting. Both assays
showed higher levels of phosphorylation in the index patient
cells compared with healthy controls (Supplementary Figure S2),
indicating that mTOR kinase signaling was highly active in the
patient cells.
To determine whether lymphoid tumors and TCF3-PBX1
BCP-ALLs are typically sensitive to mTOR inhibitors we compared
the drug sensitivities of the index patient cells to cells from
patients with other lymphoid malignancies lacking the fusion and
to previously published mTOR inhibitor sensitivity data from TCF3-
PBX1 ALLs. The results showed that sensitivity to mTOR inhibitors
is variable in lymphoid tumors (Supplementary Figure S3).
Previously published ex vivo data from ﬁve TCF3-PBX1 BCP-ALLs
show limited sensitivity to mTOR inhibitors.16 These results
indicate that the index patient leukemia cells were atypically
sensitive to mTOR inhibitors possibly due to mutation to MTOR.
DISCUSSION
Using an unbiased, drug-sensitivity proﬁling assay, we found that
leukemic blasts from a TCF3-PBX1 BCP-ALL index patient obtained
at relapse were highly sensitive to the p110δ inhibitor idelalisib.
The cells from the index patient were the most sensitive to
idelalisib out of a cohort of hematological tumors, although they
were obtained from a heavily treated relapsed patient. At the time
Figure 4. PIK3CD gene expression in TCF3-PBX1 BCP-ALL. (a) PIK3CD expression was measured using RNA sequencing in 66 leukemias. The
samples from TCF3-PBX1 patient 668 (668_1 and 668_4) are shown in black. Sample 668_1 was sequenced in replicates (668_1-R1, 668_1-R2).
Gene expression levels are shown as FPKM values (fragments per kilobase of exon per million fragments mapped). (b) PIK3CD RNA-sequence
expression signal from TCF3-PBX1 BCP-ALL index patient's relapse samples (668_1 and 668_4). TCF3, PBX1 and p300 ChIP-sequence binding
signal from TCF3-PBX1 ALL patient ICN12. Input DNA is the background signal for ChIP-sequencing. The locations of PIK3CD promoters are
indicated by red bars. ChIP, chromatin immunoprecipitation.
Figure 5. CXCR4 gene expression in TCF3-PBX1 BCP-ALL. (a) CXCR4 gene expression was measured using RNA sequencing in 66 acute
leukemias. Expression levels are indicated as FPKM (fragments per kilobase of exon per million fragments mapped) values. Sample 668_1 was
sequenced twice (668_1-R1, 668_1-R2). (b) CXCR4 mRNA expression measured using qRT-PCR in the TCF3-PBX1 BCP-ALLs and ALLs lacking
TCF3-PBX1. (c) RNA-sequence expression signal from the CXCR4 locus for the index patient’s relapse samples (668_1 and 668_4). TCF3, PBX1
and p300 ChIP-sequence binding signal is from TCF3-PBX1 ALL patient ICN12. ChIP, chromatin immunoprecipitation.
Idelalisib for TCF3-PBX1 positive acute leukemia
S Eldfors et al
55
Leukemia (2017) 51 – 57
of the index patient’s relapse idelalisib was not yet approved for
clinical use. By testing of BCP-ALL cell lines, we found that two of
three TCF3-PBX1 positive cell lines were sensitive to idelalisib,
whereas TCF3-PBX1 negative cell lines were insensitive. The
idelalisib insensitive TCF3-PBX1 BCP-ALL cell line 697 harbors an
activating NRAS mutation, which may cause resistance to p110δ
inhibition. An earlier study showed pre-BCR-positive ALLs to
exhibit sensitivity to idelalisib in vitro.4 Our results with patient
samples and cell lines suggest that most TCF3-PBX1 BCP-ALLs are
highly sensitive to idelalisib, and provide additional data to
support a mechanistic rationale for the use of idelalisib in this
group of patients.
The target of idelalisib is p110δ encoded by the PIK3CD gene.
Previously, PIK3CD was identiﬁed as a regulatory target of TCF3-
PBX1 along with pre-B-cell receptor genes.4 In agreement with
these results, we observed high levels of PIK3CD expression in cells
from the TCF3-PBX1 BCP-ALL index patient. We also found that the
TCF3-PBX1 protein binds to two experimentally characterized
PIK3CD promoter regions that have been shown to drive high
PIK3CD expression in leukocytes.14,15 The ability of TCF3-PBX1 to
directly regulate expression of the idelalisib target p110δ provides
important supportive evidence for the use of this drug in TCF3-
PBX1 BCP-ALL patients.
The BTK inhibitor ibrutinib and the multi-kinase inhibitor
dasatinib, which inhibits both BTK and SRC kinases in addition
to other kinases, have been suggested to be effective against
TCF3-PBX1 BCP-ALLs.1,4,5 Dasatinib sensitivity of cells from the
index patient was similar to what has been reported previously for
TCF3-PBX1 BCP-ALL.5,16 Notably, cells from the index patient
exhibited substantially lower sensitivity to dasatinib compared
with the sensitivity of cells from a BC-CML patient. The patient
received low-dose dasatinib (25–50 mg daily) with interferon for
14 weeks, but this combination could not be administered
continuously due to the development of cytopenias and
eventually failed to prevent relapse. As the afﬁnity of dasatinib
is lower for targets in the pre-BCR pathway than for BCR-ABL, the
dose required for effective inhibition of pre-BCR signaling is likely
to be higher than doses used in CML. However, the high dasatinib
doses required may be challenging to administer in the relapse
setting due to toxicity. The cells from the ﬁrst relapse sample of
the TCF3-PBX1 BCP-ALL patient were sensitive to ibrutinib, but had
lost sensitivity in the ﬁnal relapse indicating that pre-B-cell
receptor positive BCP-ALLs can overcome BTK inhibition.
CXCR4 is the cell surface receptor for CXCL12, a chemokine
that is produced by bone marrow stromal cells. Adhesion of
leukemia cells to stromal cells through CXCR4/CXCL12 causes
adhesion-mediated drug resistance.17 Leukemia cells from the
index patient obtained at relapse expressed very high levels
of CXCR4 in contrast to diagnostic phase TCF3-PBX1 BCP-ALLs,
which did not show similar overexpression. However, chromatin-
immunoprecipitation-sequencing results revealed that TCF3-PBX1
binds to enhancer elements upstream of the CXCR4 gene,
indicating that TCF3-PBX1 does participate in the regulation of
CXCR4 expression in cells with this fusion. Overexpression of
CXCR4 was observed at relapse, thus, TCF3-PBX1 alone may not be
sufﬁcient to cause aberrant CXCR4 expression, and that in addition
to TCF3-PBX1, other alterations may be required. In breast cancer
cells, p53 represses CXCR4 expression and TP53 mutations cause
upregulation of CXCR4 expression.18 Therefore, the TP53mutations
acquired at relapse in the index patient cells could have
contributed to the upregulation of CXCR4. However, we were
unable to obtain RNA from the diagnostic phase sample that
lacked TP53 mutations to test whether CXCR4 expression was
associated with the acquisition of these mutations, and additional
studies are needed to investigate this hypothesis. Nevertheless,
our results suggest that upregulation of CXCR4 is a mechanism of
therapy resistance in relapsed TCF3-PBX1 BCP-ALL. Similar
observations have been made in BCP-ALL19 as well as pediatric
AML,20 and provide a rationale for targeting CXCR4 either by
direct antagonists such as plerixafor21 or by downstream inhibitors
of CXCR4 signaling such as dasatinib.22
In CLL, idelalisib inhibits chemokine receptor signaling
in leukemia cells causing mobilization of leukemia cells into
the bloodstream, which manifests clinically as transient
lymphocytosis.23,24 In vitro, idelalisib has been shown to reduce
chemotaxis of CLL cells towards CXCL12.25 Furthermore, PI3K
inhibitors have been shown to inhibit CXCR4 signaling in CLL
cells.26 These observations suggest that in CLL, the efﬁcacy of
idelalisib is in part owing to inhibition of CXCR4 signaling.27
CXCR4/CXCL12 interactions retain B-cell precursors in the bone
marrow niche created by CXCL12 expressing stromal cells.28 In
analogy to what has been observed in CLL, idelalisib is likely to
block CXCR4 signaling via p110δ in TCF3-PBX1 BCP-ALL causing
disruption of stromal cell contacts and mobilization of leukemia
cells into the blood. Lymphocytosis resulting from mobilization of
leukemia cells should be evaluated in future in vivo studies.
Mobilized leukemia cells are more sensitive to chemotherapy, and
idelalisib may, therefore, be an effective drug for overcoming the
therapy resistance caused by CXCR4.
Drug-sensitivity proﬁling also showed good efﬁcacy of mTOR
inhibitors towards cells from the index patient. This is in contrast
to previous in vitro drug-testing study on TCF3-PBX1 BCP-ALLs that
did not show mTOR inhibitor sensitivity,16 suggesting our
observations were speciﬁc for the index patient. MTOR mutations
have been shown to cause constitutive activation of mTOR kinase
and to induce sensitivity to mTOR inhibitors in cell lines and in
patient samples.29,30 Our results suggest that the MTOR p.
M1724_Q1725insV mutation present in the index patient cells
may have contributed to the high sensitivity to mTOR inhibitors.
In conclusion, on the basis of our results, idelalisib shows
promise as a treatment for TCF3-PBX1 BCP-ALL. Idelalisib (Zydelig,
Gilead Sciences, Foster City, CA, USA) has been approved as a
second-line treatment for CLL, follicular lymphoma and small
lymphocytic lymphoma.31 Similar to what has been observed in
these diseases, the majority of human TCF3-PBX1 BCP-ALLs
depend on pre-B-cell receptor signaling. Idelalisib is a highly
speciﬁc inhibitor of the p110δ, which is the primary PI3K isoform
in B cells, and is expressed mainly by hematopoietic cells. As a
result of this speciﬁcity, idelalisib has a relatively benign toxicity
proﬁle,32 which makes it a promising option for treating patients
with TCF3-PBX1 BCP-ALL.
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